BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 7, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 3, 2015
View Archived Issues
Chugai reviews domestic and international developments of fourth quarter 2014
Read More
Eisai profiles developments of third quarter of fiscal 2014
Read More
Pfizer profiles pipeline progress of fourth quarter 2014
Read More
Novel BRD4 inhibitors disclosed by Bayer Schering Pharma
Read More
Merck & Co. divulges novel IRAK-4 inhibitors
Read More
Astex patents novel inhibitors of discoidin domain receptors
Read More
Glenmark Pharmaceuticals discloses new RORgamma-t modulators
Read More
Novartis reports new E-NPP 2 inhibitors
Read More
Acorda reports data from phase I trial of remyelinating antibody in MS
Read More
FDA grants breakthrough therapy designation to LentiGlobin for beta-thalassemia major
Read More
DiaMedica to develop DM-199 for acute vascular diseases
Read More
Lpath submits IND application for Lpathomab in neuropathic pain
Read More
Amitiza mutual recognition procedure closes with recommendation for approval
Read More
Researchers identify potential biomarker of keloid tissue formation
Read More
Symphogen regains rights to Sym-004 and focuses on oncology
Read More
IncellDx's OncoBreast3Dx technology set for studies in detection of early-stage breast cancer
Read More
Endo completes acquisition of Auxilium Pharmaceuticals
Read More
BioMarin completes tender offer for Prosensa stock
Read More
Alnylam begins phase I/II trial of ALN-CC5 for complement-mediated diseases
Read More
Cis-urocanic acid eye drops found safe in phase I study
Read More
Phase II/III study of two Ebola vaccines initiated in Liberia
Read More
Parent Project Muscular Dystrophy awards grant to UCLA team to develop exon skipping boosters
Read More
Repros submits Androxal NDA
Read More
FDA approves Glyxambi for type 2 diabetes
Read More
Afrezza launched in U.S.
Read More
